Tamoxifen is an important adjunct chemotherapeutic agent for adjunct chemotherapeutic agent for the treatment of all treating women with breast cancer. In clinical trials involving stages of breast cancer and more recently as a chemoprotec-Ͼ30 000 women, it decreased the reoccurrence of breast cancer tive agent in women with elevated risk of developing breast by up to 50% (1). More recently, this anti-estrogen has been cancer. While beneficial for the treatment of breast cancer,
Introduction The non-steroidal anti-estrogen tamoxifen is used as an
Tamoxifen is an important adjunct chemotherapeutic agent for adjunct chemotherapeutic agent for the treatment of all treating women with breast cancer. In clinical trials involving stages of breast cancer and more recently as a chemoprotec-Ͼ30 000 women, it decreased the reoccurrence of breast cancer tive agent in women with elevated risk of developing breast by up to 50% (1) . More recently, this anti-estrogen has been cancer. While beneficial for the treatment of breast cancer,
given to women at increased risk of developing breast cancer, tamoxifen increases the risk of endometrial cancer. In with a resultant 50% decrease in the occurrence of invasive addition, it has been shown to induce liver and endometrial breast cancer (2) . A potential complication from the use of tumors in rats. Tamoxifen is genotoxic in rat liver, as tamoxifen is the induction of endometrial cancer. When used indicated by the formation of DNA adducts, through as a chemotherapeutic agent, it produced up to a 4-fold increase a metabolic pathway involving the α-hydroxylation of in endometrial tumors (1) ; when used prophylactically, the tamoxifen and N-desmethyltamoxifen. Since the contriburisk increased 2.5-fold (2) . The mechanism for the induction tion of these α-hydroxy metabolites of tamoxifen to the of these tumors is not known.
induction of endometrial tumors is presently unknown, we
In addition to causing endometrial cancer in women, of tamoxifen is sequential oxidation to 4-hydroxytamoxifen and 4-hydroxytamoxifen quinone methide (34-37; Figure 1 ). uterine peroxidase activity (39) , whereas intraperitoneal administration caused a 10-fold induction of peroxidase activity (37) . Reaction of 4-hydroxytamoxifen quinone methide with DNA in vitro leads to the formation of (E) and (Z)-α-(deoxyguanosinAlthough uterine DNA adducts were not detected after oral dosing with tamoxifen (15,39), the induction of peroxidase N 2 -yl)-4-hydroxytamoxifen (38) ; nonetheless, these adducts were not detected in hepatic DNA upon administration of activity by intraperitoneal treatment could result in an increased production of 4-hydroxytamoxifen and its quinone methide. 4-hydroxytamoxifen to rats (39, 40) . In addition, the cutaneous application of 4-hydroxytamoxifen to rats did not induce To test this possibility, a second experiment was conducted in which hepatic and uterine DNA adducts were assessed in tumors (41) .
Although activation pathways of tamoxifen in rat liver have female Sprague-Dawley rats injected intraperitoneally with tamoxifen, α-hydroxytamoxifen and 4-hydroxytamoxifen. For been established, the contribution of the α-hydroxy metabolites of tamoxifen to the toxicities observed in non-hepatic tissues comparison, additional rats were treated with 3-hydroxytamoxifen (droloxifene). This regio-isomer of 4-hydroxytamoxifen (e.g. endometrial tumors) is presently unknown. Accordingly, we have compared the extent of DNA adduct formation has been proposed as a chemotherapeutic agent for the treatment of advanced breast cancer in postmenopausal women in the livers and selected non-hepatic tissues of female Sprague-Dawley rats treated by gavage with tamoxifen, (42, 43) . Moreover, 3-hydroxytamoxifen has estrogenic activity in the bone tissue of rats (44), which suggests its potential for α-hydroxytamoxifen, N-desmethyltamoxifen, α-hydroxy-Ndesmethyltamoxifen and N,N-didesmethyltamoxifen. In addithe treatment of osteoporosis. tion, spleen lymphocytes from rats treated with tamoxifen or α-hydroxytamoxifen were assayed for the induction of mutants Materials and methods in the hypoxanthine phosphoribosyl transferase (Hprt) gene.
Chemicals
The route of drug administration may have an important Tamoxifen, salmon testes DNA, bis(2-hydroxyethyl)iminotris(hydroxymethyl)-bearing on the metabolic activation pathways of tamoxifen.
methane (Bis-Tris), trioctanoin and the enzymes used in DNA hydrolysis were purchased from Sigma (St Louis, MO). Carrier-free [γ- 32 HPLC analyses of 32 P-post-labeled samples were conducted with a 5 µ To a stirred suspension of 95% potassium t-butoxide (2.6 g, 22 mmol) in Delta-Pak C 18 -100 column (0.39 cmϫ15 cm; Waters) using a Waters system, n-hexane (13 ml), kept under nitrogen at room temperature, were added as described above, equipped with a Radiomatic Flo-One Model A-500 onsequentially n-propylbenzene (3 ml, 21.5 mmol), n-butyllithium (1.6 M in line radioactivity detector (Packard Instruments, Meriden, CT).
hexane, 12 ml, 19.2 mmol) and N,N,NЈ,NЈ-tetramethylethylenediamine (6.5 ml, (E)-α-(Deoxyguanosin-N 2 -yl)tamoxifen was weighed to an accuracy of 43 mmol). The ensuing red suspension was stirred at room temperature for 0.1 µg with a Sartorius 4504 Mp8-1 ultra-micro balance.
an additional period of 30 min and then cooled to -70°C. A solution of UV spectra were recorded with either a Beckman DU-40 UV/vis or a 4-hydroxybenzophenone (2.5 g, 12.6 mmol) in tetrahydrofuran (20 ml) was Shimadzu 1202 UV/vis spectrophotometer.
subsequently added over~45 min, and the mixture was allowed to reach room 1 H NMR spectra were obtained either on a Varian Unity 300 spectrometer, temperature. After 2 h, the reaction was quenched by addition of a saturated operating at 300 MHz, or a Bruker AM500 spectrometer, operating at ammonium chloride solution (350 ml) and the organic materials were extracted 500 MHz. 13 poured into ice water. Following extraction with methylene chloride, the alkOPhH), 7.20-7.37 (10H, m, PhH). 13 Sprague-Dawley rats treated by gavage or intraperitoneally with seven daily (39) . Following sequential extraction of unbound materials with diethyl ether doses of tamoxifen and its derivatives a and n-butanol, both of which had been presaturated with 5 mM Bis-Tris, 0.1 mM EDTA (pH 7.1), the modified DNA was precipitated with NaCl and Treatment Body Liver Uterus ethanol, and redissolved in 5 mM Bis-Tris, 0.1 mM EDTA (pH 7.1) at a weight (g) (mg) concentration of~1 mg/ml. The DNA was hydrolyzed to nucleosides by change treatment with DNase I, followed by alkaline phosphatase and phosphodiester-(g) ase I (49) . The adducts were then partitioned into n-butanol, which had been presaturated with 5 mM Bis-Tris, 0.1 mM EDTA (pH 7.1) and the n-butanol Gavage was evaporated. The residue was redissolved in methanol and purified by Solvent 29 Ϯ 8 11.45 Ϯ 1.64 378 Ϯ 45 HPLC, at a flow rate of 2 ml/min, using a 17 min linear gradient of 0-60% Tamoxifen 7 Ϯ 5 b 11.67 Ϯ 0.95 299 Ϯ 48 acetonitrile in 100 mM ammonium acetate (pH 5. α-Sulfoxy-N-desmethyltamoxifen was prepared from α-hydroxy-N-desmewere treated daily for 7 days with equimolar doses of α-hydroxytamoxifen thyltamoxifen and reacted with DNA as detailed in Gamboa da Costa et al.
. (E)-4-[4-(2-Dimethylaminoethoxy)phenyl]-3,4-diphenylbut-3-en-2-ol (α-hydroxytamoxifen) N,N-Didesmethyltamoxifen
(20.9 mg/kg), 3-hydroxytamoxifen citrate (31.1 mg/kg), (E, Z)-4-hydroxyta- (32) . Following extraction of unbound materials and precipitation, the modified moxifen (20.9 mg/kg) or the solvent (200 µl trioctanoin) alone. Twenty-four DNA was hydrolyzed to nucleosides as described above. HPLC analysis hours following the last treatment, the rats were killed. Four animals from indicated one major adduct, which has been characterized as (E)-α-(deoxygueach group were used to determine the type and extent of DNA adduct anosin-N 2 -yl)-N-desmethyltamoxifen (32) .
formation in the liver and uterus. The remaining rats were used to assess the 4-Hydroxytamoxifen quinone methide was prepared from (E,Z)-4-hydroxyinduction of hepatic cytochrome P-450 and uterine peroxidase activities. tamoxifen and reacted with DNA as described in Marques and Beland Hepatic microsomes and uterine extracts were prepared and hepatic (38) . Two major adducts, which have been identified as (E)-and (Z)-α-microsomal and uterine peroxidase activities were measured as described (deoxyguanosin-N 2 -yl)-4-hydroxytamoxifen (38) , were detected by HPLC.
previously (39) . Treatment of animals 32 P-Post-labeling analyses Rats were treated according to the protocol of White et al. (12) . Specifically, 32 and from 40 to 60 min, a linear gradient to 100% solvent B. The eluent from Twenty-four hours after the last treatment, four animals from each of the the first 15 min was diverted from the detector to avoid interference from the groups treated with tamoxifen and its derivatives were killed by exposure to high amounts of radioactivity associated with free 32 P, unreacted [γ-32 P]ATP carbon dioxide. The livers, spleens, thymuses and uteri were quickly excised and 32 P-post-labeled normal nucleotides. The adducts formed in vivo were and bone marrow was aspirated from the femurs and humeri. Hepatic nuclei characterized by comparison with the DNA adduct standards modified in vitro were isolated by the method of Basler et al. (51) and DNA was prepared from with α-acetoxytamoxifen, α-sulfoxy-N-desmethyltamoxifen and 4-hydroxytaliver nuclei, spleen, thymus, uterus and bone marrow by slight modifications of moxifen quinone methide. The adduct levels were quantified through the method described in Beland et al. (52) to conduct DNA adduct analyses.
comparison to a 32 P-post-labeled DNA adduct standard containing (E)-α-Four additional rats from the tamoxifen, α-hydroxytamoxifen, N-desmethylta-(deoxyguanosin-N 2 -yl)tamoxifen at a level of 5.2 adducts/10 6 nucleotides. moxifen and control groups were killed 1 and 3 months after the last treatment.
Lymphocyte Hprt mutant assay DNA adduct analyses were conducted on liver DNA from these rats and the Hprt mutant frequency was assessed in spleen lymphocytes. One ENU-treated
The lymphocyte Hprt mutant assay was performed as described previously (54, 55) . Briefly, spleens were removed aseptically from rats, teased apart with rat was killed at each of these time points for Hprt mutant frequency analysis.
In a separate experiment, eight female Sprague-Dawley rats (8 weeks old, 25-26 gauge needles and washed with cold, supplemented phosphate-buffered saline to release the cells. Lymphocytes were isolated by Accu-Paque (Accurate 220 Ϯ 19 g, obtained from the breeding colony at the National Center for Toxicological Research) were treated by intraperitoneal injection, according Chemical, Westbury, NY) density-gradient centrifugation. For each sample, two sets of lymphocyte cultures were established in three 96-well microtiter to the protocol of Pathak et al. (37) , with seven daily doses of tamoxifen (20 mg/kg; 54 µmol/kg; dissolved in 200 µl trioctanoin). Eight additional rats plates. One set of plates was used for determining the cloning efficiency under alone, each compound caused a significant reduction in body 4-hydroxytamoxifen or the solvent alone. Twenty-four hours following the last treatment, the rats were killed. The data are expressed as the mean Ϯ weight when measured 1 day after the last treatment (Table I) .
SD. The limit of detection was~3 adducts/10 8 nucleotides.
Liver weight was not affected, except by α-hydroxytamoxifen b Significantly different (P Ͻ 0.05) from rats treated with solvent alone as administered intraperitoneally (Table I) . Uterine weight tended determined by one-way ANOVA followed by Dunnett's test.
to decrease, but the change was only significant with the derivatives given intraperitoneally (Table I) . Spleen and thymus non-selective conditions, and the other was supplemented with 2.5 µg/ml weights were also measured in rats dosed by gavage; these 6-thioguanine and used to select 6-thioguanine-resistant lymphocytes. Both did not differ from the solvent-treated control rats (data not sets of plates were incubated in a humidified atmosphere of 5% CO 2 in air shown). Additional rats were administered tamoxifen, and after 11 days the plates were scored for clone formation (56). The cloning α-hydroxytamoxifen and N-desmethyltamoxifen by gavage for efficiency for each set of cultures and the frequency of 6-thioguanine-resistant lymphocytes were then calculated.
7 days and killed 1 and 3 months after the last dose. With a Female Sprague-Dawley rats were treated by intraperitoneal injection with seven daily doses of 54 µmol/kg tamoxifen. Additional animals were treated with equimolar doses of α-hydroxytamoxifen, 3-hydroxytamoxifen citrate, 4-hydroxytamoxifen or the solvent alone. Twenty-four hours following the last treatment, the rats were killed. The data are presented as the mean Ϯ SD. Hepatic enzyme activities are expressed in pmol/mg protein/min; uterine peroxidase activity is given as mU/mg protein.
b Significantly different (P Ͻ 0.05) from rats treated with solvent alone as determined by one-way ANOVA followed by Dunnett's test.
these rats, there were no significant differences in body or extent of mutant induction in spleen T-lymphocytes. Compared with rats administered the solvent alone, there was no signiorgan weights compared with the controls.
ficant increase in mutants ( Figure 4) . A substantial increase in DNA adduct analyses mutant frequency was observed with ENU, which served as a DNA adducts were assessed by 32 P-post-labeling in conjunction positive control. with HPLC. When measured 1 day after the last treatment, Induction of hepatic and uterine enzyme activities tamoxifen ( Figure 2B ) and α-hydroxytamoxifen ( Figure 2C ) gave two major adducts (b and c) and one minor adduct (a) Hepatic microsomal preparations from rats treated intraperitoneally for 7 days with tamoxifen, α-hydroxytamoxifen, in the liver DNA from rats treated by gavage. These adducts were not observed in control rats (Figure 2A) . A similar pattern 3-hydroxytamoxifen or 4-hydroxytamoxifen were assayed for the induction of various cytochrome P-450 activities. Each of was observed in rats administered tamoxifen and α-hydroxytamoxifen intraperitoneally (data not shown). One the compounds, with the exception of 3-hydroxytamoxifen, induced a significant increase in ethoxyresorufin O-deethylase major adduct (b) and one minor adduct (a) were detected in liver DNA from rats dosed with N-desmethyltamoxifen ( Figure  activity , a measure of cytochrome P-450 1A1/1A2 (Table III) . None of the compounds caused an increase in p-nitrophenol 2D) and α-hydroxy-N-desmethyltamoxifen ( Figure 2E ) by gavage. Adduct b co-chromatographed with (E)-α-(deoxyhydroxylase, a marker of cytochrome P-450 2E1, while the activity of aminopyrine N-demethylase, which assesses guanosin-N 2 -yl)-N-desmethyltamoxifen ( Figure 2G ), while adduct c co-chromatographed with (E)-α-(deoxyguanosincytochrome P450 3A4 activity, was increased only by α-hydroxytamoxifen. N 2 -yl)tamoxifen ( Figure 2F ). Only background levels of DNA adducts were detected in liver DNA from rats dosed by gavage Assays were also conducted to measure uterine peroxidase activity. Each of the compounds caused a significant reduction with N,N-didesmethyltamoxifen or injected intraperitoneally with 3-hydroxytamoxifen or 4-hydroxytamoxifen (data not in activity, with the values ranging from 36-48% of that found with the solvent-treated control rats (Table III) . shown). Similarly, none of the compounds resulted in an increase in DNA adducts in uterus, spleen, thymus or bone marrow DNA from rats treated by gavage or in uterus DNA Discussion from rats injected intraperitoneally (data not shown). Table II An increased incidence of endometrial cancer has been associpresents a summary of the binding data for liver DNA. When ated with the use of tamoxifen as either an adjuvant chemotheraassessed 1 day following the last dose, the relative levels of peutic or a chemopreventive agent for breast cancer (1, 2) . The binding in rats treated by gavage were α-hydroxytamoxifen mechanism for the induction of these tumors is not known, Ͼ tamoxifen µ N-desmethyltamoxifen µ α-hydroxy-N-desalthough support for a genotoxic pathway comes from the methyltamoxifen Ͼ N,N-didesmethyltamoxifen. In rats observation of DNA adducts in endometrial samples from dosed intraperitoneally, the relative order of binding was women treated with tamoxifen (57-59). Other investigators, α-hydroxytamoxifen Ͼ tamoxifen Ͼ 3-hydroxytamoxifen µ however, have not detected an increase in endometrial DNA 4-hydroxytamoxifen.
adducts (60,61) and it has been suggested that the adducts that Hepatic DNA binding levels were also assessed 1 and have been detected may not arise from tamoxifen (62). 3 months after the last dose in rats administered tamoxifen, Tamoxifen is also carcinogenic in experimental animals (3-α-hydroxytamoxifen and N-desmethyltamoxifen by gavage. 10). In rats, tumors occur in the liver (3) (4) (5) and uterus When assayed 1 month after treatment, the adduct levels had (6, 7, 10) , with the hepatic tumors being ascribed to a genotoxic decreased to 14-37% of the values obtained 1 day after the mechanism resulting from the formation of tamoxifen DNA last dose (Figure 3) . These values decreased to 6-9% of the adducts (4, (11) (12) (13) (14) (15) . Since the mechanism for the induction of initial levels when measured 3 months after dosing.
uterine tumors in any species is not known, we have used the Hprt mutant analysis rat model to investigate if a genotoxic pathway could be responsible for the endometrial tumors. In order to maximize One and 3 months after the last treatment, rats administered tamoxifen and α-hydroxytamoxifen were killed to assess the the possibility of adduct detection, the animals were also treated with tamoxifen derivatives that have been proposed to protonation of the hydroxyl functions in the acidic environment of the stomach. be proximate carcinogens in the metabolic activation of this anti-estrogen.
Although extensive hepatic DNA adduct formation occurred with tamoxifen, N-desmethyltamoxifen and their α-hydroxy DNA adducts were readily detected in hepatic DNA after treating rats with tamoxifen by either gavage or intraperitoneal metabolites, binding was not detected in other tissues. Two major pathways have been proposed for the metabolic injection. The adduct levels did not differ between the two routes of administration but are~10-fold higher than we activation of tamoxifen: sulfotransferase-catalyzed sulfation of α-hydroxytamoxifen and α-hydroxy-N-desmethyltamoxifen previously reported after intraperitoneal dosing (39) . In the present study, the adduct levels were quantified through com-(20-22,24) and peroxidase-catalyzed oxidation of 4-hydroxytamoxifen (34-37). In the rat, the sulfation of the α-hydroxy parison to a DNA standard that had been modified with tamoxifen at a known level, whereas previously (39) the levels metabolites is catalyzed by hydroxysteroid sulfotransferase a (rHSTa; 21). rHSTa is found at high levels in rat liver, but is were estimated based upon the extent of 32 P incorporation and the specific activity of the [γ-32 P]ATP used for 32 P-postexpressed at very low levels in non-hepatic tissues (64-66). α-Hydroxytamoxifen has been detected in the bile of rats labeling. These results indicate that the efficiency of labeling tamoxifen DNA adducts is~10%, which emphasizes the administered tamoxifen (67) and the weight changes we observed in the uterus (Table I) suggest that the administered importance of having well characterized DNA standards for DNA adduct quantification by 32 P-post-labeling. A similar compounds were distributed systemically. The failure to detect DNA adducts derived from α-hydroxytamoxifen or α-hydroxyfinding was reported by us when assessing DNA adduct levels from the carcinogen 4-aminobiphenyl (63) . Other investigators, N-desmethyltamoxifen in the uterus or other non-hepatic tissues is consistent with the low levels of rHSTa in extrahepatic however, have reported a considerably higher 32 P-post-labeling efficiency for tamoxifen DNA adducts when using relative tissues. It also suggests that any α-sulfoxy derivatives formed in the liver are not sufficiently stable to be transported adduct labeling as the method of quantitation (30) .
Three DNA adducts were detected in liver DNA from rats systemically. Pathak et al. (37) reported that intraperitoneal administration treated with tamoxifen. As previously reported (25,28,31,32), two of these arise from α-hydroxylation of tamoxifen (adduct of tamoxifen increased uterine peroxidase activity 10-fold, which could result in an increased oxidation of 4-hydroxytac, Figure 2B ) and N-desmethyltamoxifen (adduct b, Figure  2B ). The identity of the third adduct (adduct a, Figure 2B ) is moxifen to 4-hydroxytamoxifen quinone methide. We were unable to confirm this observation; instead of an increase in not known. It does not appear to result from N,N-didesmethyltamoxifen because this metabolite gave only very low binding uterine peroxidase activity, we detected a 2-fold decrease after intraperitoneal administration of tamoxifen and a number of to hepatic DNA (Table II) . A similar low level of hepatic DNA binding by N,N-didesmethyltamoxifen has been reported its derivatives (Table III) , which is very similar to what we previously found after treating rats with tamoxifen by gavage by Brown et al. (31) . Considering the structural similarity of tamoxifen, N-desmethyltamoxifen and N,N-didesmethyltamox- (39) . This decrease in peroxidase activity is consistent with the anti-estrogenicity of tamoxifen for the rat uterus (68) . We ifen, it is likely that the α-hydroxylation of N,N-didesmethyltamoxifen and subsequent esterification occurs in vivo. It is also obtained no evidence for DNA adducts being formed from 4-hydroxytamoxifen quinone methide in either the liver or conceivable that the presence of a primary amino group in N,Ndidesmethyltamoxifen may allow an efficient conjugation and uterus. Fan et al. (69) have suggested that 4-hydroxytamoxifen quinone methide has unusual stability; nonetheless, even if excretion. However, adduct a could still arise from α-hydroxy-N,N-didesmethyltamoxifen, formed by an alternative pathway this metabolite is formed in vivo, it either does not have sufficient reactivity or is trapped by other nucleophiles before involving N-desmethylation of α-hydroxy-N-desmethyltamoxifen, as suggested by Phillips et al. (30) . Further experireacting with DNA. Although we did not detect DNA adducts indicative of ments will be necessary to test this possibility.
When tamoxifen and α-hydroxytamoxifen were adminis-α-hydroxytamoxifen, α-hydroxy-N-desmethyltamoxifen or 4-hydroxytamoxifen in non-hepatic tissues, it is possible that tered by intraperitoneal injection, α-hydroxytamoxifen bound to hepatic DNA to a 5-fold greater extent than was found for DNA damage was occurring that was not detected by the 32 P-post-labeling analyses. For example, tamoxifen and certain tamoxifen (Table II) . This difference is similar, although of a lower magnitude, to what has been reported previously in of its metabolites have been proposed to lead to oxidative DNA damage (e.g. 8-oxodeoxyguanosine; 70,71), a type of F344 rats treated intraperitoneally (18). When administered by gavage, the binding of α-hydroxytamoxifen to hepatic DNA DNA adduct that would not be detected by our methodology.
To evaluate the possibility of other types of DNA damage being was only 2-fold greater than that observed with tamoxifen (Table II) and the binding of α-hydroxy-N-desmethyltamoxifen formed extrahepatically, we assessed the mutant frequency in the Hprt gene of spleen lymphocytes from rats treated with did not exceed that found with N-desmethyltamoxifen (Table  II) . These results were unexpected because in F344 rats, tamoxifen and α-hydroxytamoxifen. When measured 1 and 3 months after the last dose, no increase in the mutant frequency α-hydroxytamoxifen gave 30-fold higher hepatic DNA adduct levels than tamoxifen when administered by gavage (30) .
was observed (Figure 4) , thus supporting the conclusion that tamoxifen and its metabolites are not genotoxic extrahepatThe relatively small difference in binding of the α-hydroxy derivatives compared with tamoxifen after gavage dosing in ically. As part of the mutagenesis experiment, hepatic DNA adduct levels were also determined and found to have decreased the current experiments may be due to the use of SpragueDawley rats or the multiple dose sequence. In addition, a to 6-9% their initial levels 3 months after the last dose ( Figure  3 ). 
